-
Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio
Tuesday, October 1, 2019 - 1:48pm | 483Stifel initiated coverage on a trio of oncology-focused biotechs Tuesday, recommending buying two and staying sidelined on a third. The Analyst Benjamin Burnett initiated coverage of: bluebird bio Inc NASDAQ: BLUE) with a Hold rating and $109 price target. Iovance Biotherapeutics...
-
Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch
Thursday, November 2, 2017 - 1:48pm | 661The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX)'s third-quarter results. Given the buoyancy surrounding Ingrezza, analysts scrambled to designate Neurocrine as their top mid-cap pick. Ingrezza...